Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients.

[1]  J. Grandis,et al.  Epidermal growth factor receptor biology in head and neck cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Simcock,et al.  Erlotinib induced skin rash spares skin in previous radiotherapy field. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[4]  D. Agus,et al.  Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies , 2005, British Journal of Cancer.

[5]  R. Perez-soler,et al.  Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Alain Spatz,et al.  Cutaneous side-effects of kinase inhibitors and blocking antibodies. , 2005, The Lancet. Oncology.

[7]  S. Chan,et al.  Epidermal Growth Factor as a Biologic Switch in Hair Growth Cycle* , 2003, Journal of Biological Chemistry.

[8]  B. Dubray,et al.  Altered proliferation and differentiation of human epidermis in cases of skin fibrosis after radiotherapy. , 2002, International journal of radiation oncology, biology, physics.

[9]  J O Archambeau,et al.  Pathophysiology of irradiated skin and breast. , 1995, International journal of radiation oncology, biology, physics.